Bispecific CD19/22 CAR therapy in children and young adults with ALL
Bispecific CD19/22 CAR therapy in children and young adults with ALL
ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas
Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor relapsed/refractory ALL
Alpha/beta T-cell and B-cell depletion haplo-HSCT is an effective treatment for children with acute leukaemia
Matched targeted therapy for paediatric patients with relapsed, refractory or high-risk leukemias
Updates on the ELIANA trial for acute lymphocytic leukaemia in young patients
The benefits of a stem cell transplant after CAR T-cell therapy in paediatric patients
Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy
Latest analysis of the ELIANA trial for acute lymphocytic leukaemia
Four cycles of chemotherapy as effective as six for diffuse large B-Cell lymphoma
Latest advances in acute lymphoblastic leukaemia and paediatrics in HARMONY
Managing uncertainty in Spitz Nevi melanoma